CNTX Stock Overview
A biopharmaceutical company, develops products for the treatment of solid tumors. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Context Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.25 |
| 52 Week High | US$2.75 |
| 52 Week Low | US$0.89 |
| Beta | 2.1 |
| 1 Month Change | -16.67% |
| 3 Month Change | -31.69% |
| 1 Year Change | 4.81% |
| 3 Year Change | -50.59% |
| 5 Year Change | n/a |
| Change since IPO | -75.49% |
Recent News & Updates
Recent updates
We Think Context Therapeutics (NASDAQ:CNTX) Can Afford To Drive Business Growth
Aug 15
We're A Little Worried About Context Therapeutics' (NASDAQ:CNTX) Cash Burn Rate
Mar 27Here's Why Context Therapeutics (NASDAQ:CNTX) Must Use Its Cash Wisely
Sep 28Will Context Therapeutics (NASDAQ:CNTX) Spend Its Cash Wisely?
Jun 05Context to focus on ELONA trial, CLDN6 program, extends cash runway into 1Q24
Sep 27We're Keeping An Eye On Context Therapeutics' (NASDAQ:CNTX) Cash Burn Rate
Sep 15Context Therapeutics GAAP EPS of -$0.25 in-line
Aug 11Context Therapeutics, Menarini to collaborate on breast cancer treatment combo trial
Aug 02Companies Like Context Therapeutics (NASDAQ:CNTX) Are In A Position To Invest In Growth
May 28Context Therapeutics: A New Biotech Issue With A Low Valuation And Significant Potential
Nov 02Shareholder Returns
| CNTX | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 13.6% | -0.6% | -0.2% |
| 1Y | 4.8% | 3.0% | 25.8% |
Return vs Industry: CNTX exceeded the US Pharmaceuticals industry which returned 3% over the past year.
Return vs Market: CNTX underperformed the US Market which returned 25.6% over the past year.
Price Volatility
| CNTX volatility | |
|---|---|
| CNTX Average Weekly Movement | 11.9% |
| Pharmaceuticals Industry Average Movement | 10.8% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 18.6% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CNTX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CNTX's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 5 | Martin Lehr | www.contexttherapeutics.com |
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.
Context Therapeutics Inc. Fundamentals Summary
| CNTX fundamental statistics | |
|---|---|
| Market cap | US$93.75m |
| Earnings (TTM) | -US$30.15m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.1x
P/E RatioIs CNTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CNTX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$30.15m |
| Earnings | -US$30.15m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.40 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did CNTX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/05 09:04 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Context Therapeutics Inc. is covered by 6 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Kolbert | D. Boral Capital LLC. |
| Soo Romanoff | Edison Investment Research |
| Emily Bodnar | H.C. Wainwright & Co. |